Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Yuji, Uno"'
Autor:
Yui Hirata-Nozaki, Takayuki Ohkuri, Kenzo Ohara, Takumi Kumai, Marino Nagata, Shohei Harabuchi, Akemi Kosaka, Toshihiro Nagato, Kei Ishibashi, Kensuke Oikawa, Naoko Aoki, Mizuho Ohara, Yasuaki Harabuchi, Yuji Uno, Hidehiro Takei, Esteban Celis, Hiroya Kobayashi
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-16 (2019)
Abstract Background Head and neck squamous cell carcinoma (HNSCC) originates from squamous epithelium of the upper aerodigestive tract and is the most common malignancy in the head and neck region. Among HNSCCs, oropharynx squamous cell carcinoma (OS
Externí odkaz:
https://doaj.org/article/3c9e9e4d83c24aa29d3cb2439f369956
Autor:
Yuji Uno1, Naoko Akiyama1, Sayaka Yuzawa1, Masahiro Kitada2, Hidehiro Takei1 htakei@asahikawa-med.ac.jp
Publikováno v:
CytoJournal. 5/12/2020, Vol. 17, p1-5. 5p.
Autor:
Yuji Uno, Hiroki Tanaka, Keita Miyakawa, Naoko Akiyama, Yuki Kamikokura, Sayaka Yuzawa, Masahiro Kitada, Hidehiro Takei, Mishie Tanino
Publikováno v:
Human pathology.
Human telomerase reverse transcriptase (hTERT) is highly expressed in various cancers, including breast cancer. Although telomere elongation is an essential role for hTERT, the nuclear export after oxdative stress has also been shown in several cance
Autor:
Yoshinobu Ohsaki, Kanako C. Hatanaka, Takaaki Sasaki, Noriko Hirai, Yutaka Hatanaka, Shunsuke Okumura, Yasuhiro Umekage, Yuji Uno, Yoshinori Minami, Shinichi Chiba
Publikováno v:
Translational Lung Cancer Research. 10:3737-3744
Background Combination therapy with the B-Raf inhibitor, dabrafenib, and the MEK inhibitor, trametinib (DT) is commonly used to treat patients with B-Raf proto-oncogene, serine/threonine kinase V600E (BRAF V600E)-mutated non-small cell lung cancer (N
Autor:
Yuji Uno, Hiroki Tanaka, Keita Miyakawa, Naoko Akiyama, Yuki Kamikokura, Sayaka Yuzawa, Masahiro Kitada, Hidehiro Takei, Mishie Tanino
Publikováno v:
SSRN Electronic Journal.
Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in
Autor:
Noriko, Hirai, Yutaka, Hatanaka, Kanako C, Hatanaka, Yuji, Uno, Shin-Ichi, Chiba, Yasuhiro, Umekage, Yoshinori, Minami, Shunsuke, Okumura, Yoshinobu, Ohsaki, Takaaki, Sasaki
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Combination therapy with the B-Raf inhibitor, dabrafenib, and the MEK inhibitor, trametinib (DT) is commonly used to treat patients with B-Raf proto-oncogene, serine/threonine kinase V600E (BRAF V600E)-mutated non-small cell lung cancer (
Publikováno v:
Cancer Research. 81:1103-1103
Background: Since the discovery of the oncogenic mutation B-Raf proto-oncogene, serine threonine kinase (BRAF) V600E, dabrafenib and trametinib (DT) combination therapies have been shown to have great anti-tumor activities against V600E-mutated non-s
Autor:
Toshihiro Nagato, Kei Ishibashi, Shohei Harabuchi, Naoko Aoki, Esteban Celis, Akemi Kosaka, Mizuho Ohara, Hidehiro Takei, Marino Nagata, Yui Hirata-Nozaki, Kensuke Oikawa, Takumi Kumai, Takayuki Ohkuri, Hiroya Kobayashi, Yuji Uno, Kenzo Ohara, Yasuaki Harabuchi
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-16 (2019)
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-16 (2019)
Background Head and neck squamous cell carcinoma (HNSCC) originates from squamous epithelium of the upper aerodigestive tract and is the most common malignancy in the head and neck region. Among HNSCCs, oropharynx squamous cell carcinoma (OSCC) has a
Publikováno v:
CytoJournal
Objective: Intraoperative evaluation of sentinel lymph nodes (SLNs) for patients with breast cancer is widely performed with frozen section (FS), cytology, or a combination of both. Touch imprint cytology (TIC) reportedly has an equivalent sensitivit